MajorSelective serotonin reuptake inhibitor (SSRI)×Class Ic antiarrhythmic with beta-blocking activity
Updated · Methodology
Mechanism
Paroxetine strongly inhibits the enzyme CYP2D6 (paroxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP2D6, CYP3A4 and CYP1A2 metabolise propafenone, and CYP2D6 inhibitors, paroxetine among them, raise its blood levels (propafenone label, US Food and Drug Administration, FDA). The documents give no figures for this pair. With another strong CYP2D6 inhibitor, fluoxetine, peak concentration and area under the concentration curve (AUC) rose by 39% and 50% for S-propafenone and by 71% and 50% for R-propafenone (propafenone SmPC, AEMPS). Excess propafenone can cause arrhythmias and exaggerated beta-blocking activity, and propafenone itself may prolong the QT interval, although QRS widening makes this effect hard to assess (propafenone FDA label). According to the paroxetine FDA label, higher levels of CYP2D6 substrates that prolong the corrected QT interval (QTc) may lengthen QTc further and lead to torsade de pointes, other serious arrhythmias and sudden death (paroxetine FDA label).
Symptoms
Propafenone most often causes dizziness, cardiac conduction disorders and palpitations (propafenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess propafenone, the electrocardiogram (ECG) shows a longer PQ interval and a wider QRS complex. Sinus rhythm slows, and atrioventricular block, ventricular tachycardia and ventricular fibrillation appear. Weaker heart contraction lowers blood pressure, in severe cases down to shock (propafenone SmPC, AEMPS). New or worsened arrhythmias with propafenone include sudden death and torsade de pointes, which causes palpitations, dizziness and fainting (propafenone label, US Food and Drug Administration, FDA).
Management
Avoid the combination where possible. In its September 2026 version, the US Food and Drug Administration (FDA) paroxetine label contraindicates paroxetine with drugs that prolong the QT interval and are CYP2D6 substrates. Propafenone is a CYP2D6 substrate, but its FDA label only says it may prolong the QT interval, so the editors do not treat the combination as contraindicated (paroxetine and propafenone FDA labels). The Spanish SmPCs are softer. With paroxetine, a lower propafenone dose may be enough; monitor patients on CYP2D6 inhibitors closely and adjust the propafenone dose to response (propafenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use paroxetine with caution together with antiarrhythmics (paroxetine SmPC, AEMPS). If the patient still takes both, adjust the propafenone dose under cardiology supervision with an electrocardiogram (ECG) and repeated blood pressure checks, and raise it only after 3–4 days of treatment (propafenone SmPC, AEMPS). If the QRS complex or the corrected QT interval lengthens, or second- or third-degree atrioventricular block appears, lower the propafenone dose or interrupt treatment until the ECG returns to normal (propafenone SmPC, AEMPS). Do not add a CYP3A4 inhibitor such as ketoconazole, erythromycin or grapefruit juice: avoid taking propafenone with a CYP2D6 inhibitor and a CYP3A4 inhibitor at the same time (propafenone FDA label). Propafenone may raise the levels of drugs metabolised by CYP2D6 (propafenone SmPC, AEMPS), and CYP2D6 partly metabolises paroxetine (paroxetine FDA label). For this reason, consider the lowest paroxetine dose within the therapeutic range (paroxetine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Frosinor 20 mg (paroxetina) (2026)– AEMPS CIMA, Frosinor 20 mg comprimidos recubiertos con película, nº registro 59466, secciones 4.3, 4.4 y 4.5
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Propafenona (nº registro 55538), sección 4.5 (2019)– AEMPS, CIMA, nº registro 55538 (Rytmonorm 150 mg comprimidos recubiertos), revisión 03/2019, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 4.9
- FDA: Propafenone hydrochloride tablets (propafenone) prescribing information (2025)– FDA, DailyMed setid c65253ab-937f-4982-b841-69c2b9f9ccdb (Strides Pharma Science), revisión 09/2025 (versión 3), secciones 2, 5.1, 5.3, 5.4, 7.1, 12.2 y 12.3